HOUT-16. THE COST EFFECTIVENESS OF TUMOR TREATING FIELDS TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA BASED ON THE EF-14 TRIAL

BACKGROUND: With the EF-14 Trial reporting a 5-year survival rate of 13% for newly diagnosed Glioblastoma (GBM) patients treated with TTFields and maintenance temozolomide (TMZ) chemotherapy, a relevant number of patients will become long-term survivors. The impact on resource utilization from a hea...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Guzauskas, Gregory, Wang, Bruce CM, Pollom, Erqi, Stieber, Volker W, Garrison, Lou
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2018
Témata:
Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6217126/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.484
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky